Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.
Cazzaniga ME, Pronzato P, Amoroso D, Bernardo A, Biganzoli L, Bisagni G, Blasi L, Bria E, Cognetti F, Crinò L, De Laurentiis M, Del Mastro L, De Placido S, Beano A, Ferraù F, Foladore S, Forcignanò R, Gamucci T, Garrone O, Gennari A, Giordano M, Giotta F, Giovanardi F, Latini L, Livi L, Marchetti P, Mattioli R, Michelotti A, Montemurro F, Putzu C, Riccardi F, Ricciardi G, Romagnoli E, Sarobba G, Spazzapan S, Tagliaferri P, Tinari N, Tonini G, Turletti A, Verusio C, Zambelli A, Mustacchi G. Cazzaniga ME, et al. Among authors: bisagni g. Cancers (Basel). 2023 Dec 25;16(1):117. doi: 10.3390/cancers16010117. Cancers (Basel). 2023. PMID: 38201545 Free PMC article.
Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
Bozzetti C, Musolino A, Camisa R, Bisagni G, Flora M, Bassano C, Martella E, Lagrasta C, Nizzoli R, Personeni N, Leonardi F, Cocconi G, Ardizzoni A. Bozzetti C, et al. Among authors: bisagni g. Am J Clin Oncol. 2006 Apr;29(2):171-7. doi: 10.1097/01.coc.0000204405.96572.f9. Am J Clin Oncol. 2006. PMID: 16601438
Prospective, multicenter, randomized trial of a new organizational modality for providing information and support to cancer patients.
Passalacqua R, Caminiti C, Campione F, Diodati F, Todeschini R, Bisagni G, Labianca R, Dalla Chiesa M, Bracci R, Aragona M, Artioli F, Cavanna L, Masina A, De Falco F, Marzocchini B, Iacono C, Contu A, Di Costanzo F, Bertetto O, Annunziata MA. Passalacqua R, et al. Among authors: bisagni g. J Clin Oncol. 2009 Apr 10;27(11):1794-9. doi: 10.1200/JCO.2007.15.0615. Epub 2009 Mar 9. J Clin Oncol. 2009. PMID: 19273715 Clinical Trial.
Cisplatin and etoposide in advanced colorectal carcinoma.
Passalacqua R, Bisagni G, Cocconi G, Boni C, Di Blasio B, Ceci G. Passalacqua R, et al. Among authors: bisagni g. Ann Oncol. 1991 Oct;2(9):687-8. doi: 10.1093/oxfordjournals.annonc.a058050. Ann Oncol. 1991. PMID: 1742225 Free article.
Aminoglutethimide in advanced breast cancer.
Ceci G, Passalacqua R, Bisagni G, Bella M, Cocconi G. Ceci G, et al. Among authors: bisagni g. Tumori. 1985 Oct 31;71(5):483-9. doi: 10.1177/030089168507100512. Tumori. 1985. PMID: 2865833
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.
Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D, Zerbini A, Camisa R, Chernyschova N, Bisagni G, Loupakis F, Ruzzo A, Neri TM, Ardizzoni A. Negri FV, et al. Among authors: bisagni g. Pharmacogenomics J. 2014 Feb;14(1):14-9. doi: 10.1038/tpj.2012.54. Epub 2013 Jan 8. Pharmacogenomics J. 2014. PMID: 23296156 Clinical Trial.
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group; BIG 1-98 Collaborative Group. Giobbie-Hurder A, et al. Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380. Clin Trials. 2009. PMID: 19528136 Free PMC article. Clinical Trial.
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.
Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, Ferzi A, Silva RR, Gamucci T, Clavarezza M, Stocchi L, Fabi A, Cognetti F, Torrisi E, Crivellari D. Gori S, et al. Among authors: bisagni g. Ann Oncol. 2012 Jun;23(6):1436-41. doi: 10.1093/annonc/mdr474. Epub 2011 Oct 29. Ann Oncol. 2012. PMID: 22039084 Free article.
115 results